ClinicalTrials.gg
Active, not recruitingNCT06701331Start Up JapanUpdated Feb 23, 2026

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Placebo and Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Active, not recruiting at 25 sites in Japan. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
12th of 17
99 · median 272
Started
2024
with 3 others
Phase 3
12 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 12th largest by enrollment, is one of 4 that started in 2024, is one of 12 in phase 3, and was the 15th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Pediatric atopic dermatitis (AD), also known as childhood eczema, is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to assess the change in disease activity (Efficacy) and to assess the safety of upadacitinib in combination with topical corticosteroids (TCS) in pediatric participants 2 to 11 years of age in Japan with moderate to severe AD who are candidates for systemic therapy.

Upadacitinib is approved for the treatment of moderate to severe AD in adults and adolescents 12 years of age and older in many countries, including Japan. This study comprises a 35-day screening period; a 12-week, randomized, double-blind treatment period where there will be a 1 in 2 chance that a participant is assigned placebo. This will be followed by an open-label upadacitinib treatment period up to Week 52.

Around 98 participants will be enrolled in the study at approximately 35 sites in Japan.

Participants will receive upadacitinib oral tablets, or matching placebo, once daily (or an adult equivalent oral solution dose twice a day) for up to 52 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by clinical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Upadacitinib
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A minimum weight of 10 kg and weight and height ≥ -2.0 SD for their age according to Japanese standard growth charts at the Baseline visit.
  • Atopic Dermatitis (AD), according to Hanifin and Rajka criteria, with onset of symptoms at least 6 months prior to Baseline.
  • Eczema Area and Severity Index (EASI) score ≥ 16; validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) score ≥ 3; ≥ 10% body surface area (BSA) of AD involvement at the Baseline visit; and Baseline weekly average of daily WIS or WSI-NRS ≥ 4.
  • Participant has applied a topical, additive-free, bland emollient or moisturizer twice daily for at least 7 days before the Baseline visit.
  • Documented history (within 6 months of the Baseline visit) of inadequate response or intolerance to topical (TCS) and/or topical calcineurin inhibitors (TCI) or a systemic immunomodulating therapy, or medical inadvisability of available systemic therapy (e.g., because of important side effects or safety risks).

Exclusion criteria

Exclusion Criteria:

  • Participants that have current and/or history of other active skin diseases (e.g., psoriasis or Netherton syndrome or lupus erythematosus) or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline visit or that would interfere with the appropriate assessment of AD lesions.
  • Participants that have used topical treatments for AD (except for topical emollient or moisturizer treatments) including but not limited to TCS, TCI, or topical PDE-4 inhibitors, within 7 days of the Baseline visit or any the following prohibited AD treatments within the specified timeframes below prior to the Baseline visit:

    • Systemic therapy for AD, including but not limited to and cyclosporine, within 4 weeks;
    • Targeted biologic treatments within 5 half-lives (if known) or within 12 weeks, whichever is longer;
    • Phototherapy treatment, laser therapy, tanning booth use, or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Upadacitinib + Topical Corticosteroids (TCS)

    Participants will be randomized to receive the upadacitinib daily adult equivalent dose in combination with TCS once a day (QD) during the double-blind and open label treatment periods for a total of 52 weeks

    Drug: Upadacitinib

  • Placebo comparator
    Placebo / Upadacitinib + Topical Corticosteroids (TCS)

    Participants will receive placebo orally once a day (QD) in combination with TCS for 12 weeks in the double-blind treatment period. At Week 12 participants will then be switched to receive open-label upadacitinib daily adult equivalent dose in combination with TCS.

    Drug: Placebo · Drug: Upadacitinib

Interventions

  • DrugPlacebo

    Tablets taken orally once a day (Or equivalent oral solution taken two times a day)

    Also known as: ABT-494, RINVOQ®

  • Tablets taken orally once a day (Or equivalent oral solution taken two times a day)

    Also known as: ABT-494, RINVOQ®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], An EASI 75 response is defined as a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: At Week 12

  2. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 56 weeks)

Secondary outcomes

  1. Percentage of participants achieving validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) 0/1 with a reduction from Baseline of ≥ 2 points

    vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.

    Time frame: At Week 12

  2. Percentage of participants achieving an improved (reduced) weekly average Worst Itch Scale (WIS) score of ≥ 4 from Baseline for participants equal or greater than 6 years old with a weekly average WIS of ≥ 4 at Baseline

    The WIS is an assessment tool that participants use to report the intensity of their pruritus. Using an 11-point scale (0 to 10) where 0 indicates no itching and 10 indicates worst itching possible, participants are asked 2 questions: "What was the worst itch you had today?" and "What was the worst itch you had last night?" The WIS will be administered to participants ≥ 6 years of age at the time of the Baseline visit.

    Time frame: At Week 12

  3. Percentage of participants achieving an improved (reduced) weekly average Worst Scratch/Itch numerical rating scale (WIS-NRS) score of ≥ 4 from Baseline for participants less than 6 years old with a weekly average WIS of ≥ 4 at Baseline

    The WSI-NRS is an assessment tool that evaluates a participants scratching and itching intensity at its worst in the past 24 hours as assessed by the participants parent/legally authorized representative. Intensity is assessed on an 11-point scale (0 to 10) where 0 indicates no scratching/itching and 10 indicates worst scratching/itching possible.

    Time frame: At Week 12

07

Study locations

25 sites
  • Central Clinic - Nagoya /ID# 269205
    Nagoya, Aichi-ken 464-0821, Japan
  • Fujita Health University Hospital /ID# 269201
    Toyoake, Aichi-ken 470-1192, Japan
  • Miyata Dermatology Clinic /ID# 269200
    Matsudo-Shi, Chiba 271-0092, Japan
  • Hoshikuma Dermatology ・ Allergy Clinic /ID# 270192
    Fukuoka, Fukuoka 814-0171, Japan
  • Saruta Dermatology Clinic /ID# 270416
    Fukuoka, Fukuoka 819-0042, Japan
  • Tokunaga Skin Clinic /ID# 270189
    Kasuga-shi, Fukuoka 816-0813, Japan
  • Hospital Of The University Of Occupational And Environmental Health, Japan /ID# 269206
    Kitakyushu-shi, Fukuoka 807-8556, Japan
  • Gunma University Hospital /ID# 272319
    Maebashi, Gunma 371-8511, Japan
  • Sapporo Shiroishi Dermatology Clinic /ID# 269691
    Sapporo, Hokkaido 003-0026, Japan
  • Hirase Allergie Children's Clinic /ID# 271208
    Kobe, Hyōgo 653-0836, Japan
  • Ryuseidai Children's Clinic /ID# 271400
    Tsukuba, Ibaraki 305-0008, Japan
  • University of Tsukuba Hospital /ID# 271238
    Tsukuba, Ibaraki 305-8576, Japan
  • Takeoka Dermatology Clinic /ID# 269199
    Marugame, Kagawa-ken 763-0074, Japan
  • Musashikosugi Sasamoto Pediatric And Allergy Clinic /ID# 270381
    Kawasaki-shi, Kanagawa 211-0004, Japan
  • National Hospital Organization Sagamihara National Hospital /ID# 271575
    Sagamihara, Kanagawa 252-0315, Japan
  • Aoi Dermatology Clinic /ID# 274265
    Kamimashiki-gun, Kumamoto 861-2236, Japan
  • Hayami Dermatology Clinic /ID# 269945
    Higashinari-ku, Osaka 537-0013, Japan
  • Medical corporation Kojinkai Yoshioka Dermatology Clinic /ID# 269198
    Neyagawa, Osaka 572-0838, Japan
  • Momodani Skin Clinic /ID# 270384
    Osaka, Osaka 543-0033, Japan
  • Jun Dermatology Clinic /ID# 269953
    Osaka, Osaka 558-0003, Japan
  • Dermatology and Ophthalmology Kume Clinic /ID# 271854
    Sakai-shi, Osaka 593-8324, Japan
  • Dokkyo Medical University Hospital /ID# 270367
    Mibu, Tochigi 321-0293, Japan
  • Fukuwa Clinic /ID# 269203
    Chuo-ku, Tokyo 103-0031, Japan
  • Seijo Sasamoto Pediatric Allergy Clinic /ID# 270194
    Setagaya-ku, Tokyo 157-0066, Japan
  • Saitama City Hospital /ID# 271392
    Saitama, 336-8522, Japan
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2027, 25 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 25 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 22, 2024
StartActual
Dec 22, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06701331
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Dec 22, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 23, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion